{"id":306996,"date":"2026-10-14T10:34:46","date_gmt":"2026-10-14T05:04:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=306996"},"modified":"2026-10-14T10:34:46","modified_gmt":"2026-10-14T05:04:46","slug":"rehydration-active-ingredient-and-medical-device-stocks-future-edge-watchlist","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/rehydration-active-ingredient-and-medical-device-stocks-future-edge-watchlist\/","title":{"rendered":"3 Rehydration, Active Ingredient and Medical Device Stocks With a Strong Future Roadmap: FDC, Viyash Scientific and Poly Medicure"},"content":{"rendered":"

FDC Rs 338.45, P\/E 18.05. Viyash Scientific Rs 235.02, P\/E 39.01. Poly Medicure Rs 1,600.00, P\/E 51.87. Closing prices of 13 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Rehydration, active ingredient and medical device stocks with the clearest long-term roadmaps today include FDC in oral rehydration products such as Electral along with eye, ear and anti-infective formulations, Viyash Scientific in active ingredients for human and animal health and related development services and Poly Medicure in medical devices such as infusion sets, needles, catheters and dialysis products. FY26 revenue growth was 3.9% at FDC, 14.0% at Viyash Scientific and 13.4% at Poly Medicure. P\/E stands at 18.05 for FDC (industry 37.59), 39.01 for Viyash Scientific (industry 37.59) and 51.87 for Poly Medicure (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Rehydration, active ingredient and medical device stocks give investors exposure to rehydration products, ingredients and devices that patients, doctors and hospitals use. Prescription growth, export orders and device volumes decide how much of that demand turns into profit.<\/p>\n

This list covers three rehydration, active ingredient and medical device stocks: FDC for oral rehydration products such as Electral along with eye, ear and anti-infective formulations, Viyash Scientific for active ingredients for human and animal health and related development services and Poly Medicure for medical devices such as infusion sets, needles, catheters and dialysis products. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n